Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Oral Minoxidil Side Effects: Severity Distribution by Patient Phenotype

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Most common effect / hypertrichosis, 15.1% of 1,404 patients [1]
  • Fluid retention / 1.3% at hair-loss doses [1]; 7% temporary edema at antihypertensive doses [2]
  • Heart rate / mean +2.67 beats/min at 5 mg/day or less [3]
  • Stopped for side effects / 1.2% systemic, 0.5% hypertrichosis [1]
  • Dose association / each extra 1 mg/day, estimated mean difference of 17.9% in hypertrichosis risk [4]
  • Approval / not FDA-approved for hair loss [2]

What the published rates are

The largest set of numbers comes from a retrospective multicentre study of 1,404 patients (943 women, 461 men; mean age 43) treated at least three months, with no control group [1]. Hypertrichosis occurred in 15.1% and led to withdrawal in 14 patients (0.5%); lightheadedness occurred in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%, while headache, periorbital edema and insomnia each occurred in under 0.5% [1]. Systemic effects led to discontinuation in 29 patients (1.2%), and the authors reported no life-threatening adverse effects [1].

A 2025 meta-analysis of studies using 5 mg/day or less found no significant change in systolic blood pressure (-0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic pressure (-1.25, 95% CI -3.21 to 0.71), and a small rise in heart rate (+2.67 beats/min, 95% CI 0.34 to 5.01) [3]. Hypotensive symptoms were reported in 119 patients (5.0%) with no hypotensive episodes [3].

Which patients does the label single out?

The tablet label identifies compromised kidney function as a factor associated with pericardial effusion. Pericardial effusion, occasionally with tamponade, was observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function [2]. That figure comes from antihypertensive-dose experience, not from hair-loss cohorts.

The label also notes that the extra hair growth is especially disturbing to children and women, and that patients should be told about this effect before treatment begins [2].

Dose is the variable with numbers

A 2022 meta-regression across six studies in androgenetic alopecia found that each additional 1 mg/day was associated at six months with a 47.1 hairs/cm² increase in total hair density, estimated mean differences of 17.9% in hypertrichosis risk and 4.8% in cardiovascular adverse-event risk [4]. These associations do not establish that raising a dose causes those changes [4]. The tablet label's own figures — temporary edema in 7% of patients not edematous at the start, ECG T-wave changes in about 60%, pericardial effusion in about 3%, hypertrichosis in about 80% — come from antihypertensive doses [2].

Frequently asked questions

How common are side effects from low-dose oral minoxidil?
In 1,404 patients treated at least three months, hypertrichosis occurred in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%; systemic effects led to discontinuation in 1.2%, and no life-threatening adverse effects were observed [1].
Do side-effect rates differ by patient type?
The low-dose results are not broken down by patient type [1][3]. The tablet label ties pericardial effusion to compromised kidney function at antihypertensive doses [2]. Dose is the one variable with numbers: across six studies, each additional 1 mg/day was associated with estimated mean differences of 17.9% in hypertrichosis risk and 4.8% in cardiovascular adverse-event risk, and this does not establish cause [4].
Does low-dose oral minoxidil change blood pressure or heart rate?
A 2025 meta-analysis of studies using 5 mg/day or less found no significant change in systolic or diastolic pressure and a mean heart rate rise of 2.67 beats per minute; hypotensive symptoms were reported in 5.0%, with no hypotensive episodes [3].
Does hypertrichosis go away after stopping oral minoxidil?
New hair growth stops when minoxidil is stopped, but 1 to 6 months may be needed to return to pretreatment appearance, according to the tablet label [2]. In the 1,404-patient low-dose cohort, hypertrichosis led to withdrawal in 0.5% [1].
Is oral minoxidil FDA-approved for hair loss?
No. The tablet label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication; the approved use is hypertension not manageable with maximum doses of a diuretic plus two other antihypertensive drugs [2].

References

  1. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
  2. U.S. National Library of Medicine, DailyMed. Minoxidil tablets (oral), Par Health prescribing information. Minoxidil tablets (oral), Par Health label
  3. Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554-555. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis
  4. Gupta AK, Hall DC, Talukder M, Bamimore MA. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022;8(5):355-361. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
Evidence overview for Oral Minoxidil Side Effects: Severity Distribution by Patient Phenotype